New Zealand Prime Minister Jacinda Ardern has acknowledged that e-cigarettes can be an effective tool to help smokers quit, while discussing recent legislation that bans the legal purchase of tobacco for those aged 14 and under.
The Prime Minister of New Zealand stated that continuously increasing tobacco prices will not continue to aid smoking cessation, which is why alternative methods are necessary. She said that the best way to reduce smoking rates is for individuals to not start smoking in the first place.
If they smoke, they must find safe alternatives and quit smoking. That's all," Ardern said.
Speaking of New Zealand's electronic cigarette framework, Ardern acknowledges that e-cigarettes are a successful tool for people to quit smoking.
This actually allows us to push forward further action plans to reduce smoking, as there is an alternative method that has been very successful in helping people quit smoking. We know that e-cigarettes are having an impact on those who are currently quitting. Therefore, it is an important tool," said the Prime Minister of New Zealand.
New Zealand is one of the countries that allows e-cigarettes to be used more freely as a smoking cessation tool. The latest legislation will allow authorized retailers to sell a wider range of e-cigarette related products.
The legislation also requires that electronic cigarette products must obtain government approval before being sold to ensure they meet safety requirements and that the liquid ingredients do not contain any banned substances.
In 2015, a groundbreaking study was released by Public Health England (PHE) regarding electronic cigarettes. The study found that the harm to health caused by e-cigarettes is significantly lower than that caused by tobacco and that they may be a useful tool for smokers trying to quit.
Furthermore, the UK Department of Health and Social Care, along with the Office for Health Improvement and Disparities, have stated in a recent press release that the UK is likely to become the world's first country to prescribe medicinal electronic cigarettes in order to help reduce smoking rates.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
